PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15502641-16	2004	The administration of losartan resulted in inhibition of acinar cell apoptosis and down-regulation of Bax, Bak, and Bcl-2 mRNA expression.	Losartan	22-30	BCL2, apoptosis regulator	Rattus norvegicus	116-121	
15502641-17	2004	The Bax/Bcl-2 ratio was lower in losartan-treated rats than in control rats.	Losartan	33-41	BCL2, apoptosis regulator	Rattus norvegicus	8-13	
12845756-4	2000	OD values of bcl-2 (ISHH) were 0.07425 +/- 0.02029 (control group), 0.05961 +/- 0.009932 (sham operation group) and 0.07619 +/- 0.01445 (losartan-treated group) respectively, while OD values of bcl-2 (immunohistochemistry) were 0.1374 +/- 0.01367 (control group), 0.08510 +/- 0.01862 (sham operation group) and 0.1252 +/- 0.02064 (losartan-treated group).	Losartan	137-145	BCL2, apoptosis regulator	Rattus norvegicus	13-18	
11403362-4	2001	However, both losartan and UP269-6 reduced the apoptotic index and normalized the increase in Bax, decrease in Bcl-2 and increase in p53 and caspase-3 after IR.	Losartan	14-22	BCL2, apoptosis regulator	Rattus norvegicus	111-116	
12845756-4	2000	OD values of bcl-2 (ISHH) were 0.07425 +/- 0.02029 (control group), 0.05961 +/- 0.009932 (sham operation group) and 0.07619 +/- 0.01445 (losartan-treated group) respectively, while OD values of bcl-2 (immunohistochemistry) were 0.1374 +/- 0.01367 (control group), 0.08510 +/- 0.01862 (sham operation group) and 0.1252 +/- 0.02064 (losartan-treated group).	Losartan	331-339	BCL2, apoptosis regulator	Rattus norvegicus	13-18	
12845756-5	2000	bcl-2 gene expression was increased significantly in the control group and losartan-treated group as compared with sham operation group (P < 0.05).	Losartan	75-83	BCL2, apoptosis regulator	Rattus norvegicus	0-5	
12845756-8	2000	Bcl-2/bax ratio was 1.413 (control group), 1.376 (sham operation group) and 2.016 (losartan-treated group) respectively.	Losartan	83-91	BCL2, apoptosis regulator	Rattus norvegicus	0-5	
31957855-10	2020	In Losartan group, the protein expressions of JAK2, STAT3, and Bcl-2 declined, while the protein expression of Bax was increased, and the Bax/Bcl-2 ratio was also increased, which are consistent with the conditions under the treatment with the JAK-STAT pathway inhibitor AG-490.	Losartan	3-11	BCL2, apoptosis regulator	Rattus norvegicus	63-68	
9719055-7	1998	The chronic administration of losartan was associated with the normalization of apoptosis, Bax expression, and the Bcl-2/Bax ratio in treated SHR.	Losartan	30-38	BCL2, apoptosis regulator	Rattus norvegicus	115-120	
31957855-10	2020	In Losartan group, the protein expressions of JAK2, STAT3, and Bcl-2 declined, while the protein expression of Bax was increased, and the Bax/Bcl-2 ratio was also increased, which are consistent with the conditions under the treatment with the JAK-STAT pathway inhibitor AG-490.	Losartan	3-11	BCL2, apoptosis regulator	Rattus norvegicus	142-147	
18630446-18	2008	Losartan can decrease skeletal muscle cell apoptosis through regulating the ratio of Bax/Bcl-2.	Losartan	0-8	BCL2, apoptosis regulator	Rattus norvegicus	89-94	
30360036-0	2019	Changes of Bax, Bcl-2, CCR-2, MCP-1, and TGF-beta1 genes in the left ventricle of spontaneously hypertensive rat after losartan treatment.	Losartan	119-127	BCL2, apoptosis regulator	Rattus norvegicus	16-21	
22000973-9	2013	EGCG, quercetin, captopril, losartan and carvedilol markedly reduced heart weight indices and apoptotic cardiomyocyte in hypertrophic myocardium, but they had different effects on apoptotic related proteins bcl-2, p53 and c-myc.	Losartan	28-36	BCL2, apoptosis regulator	Rattus norvegicus	207-212	
23095236-8	2012	Third, losartan depressed the activation of c-jun, JNK3, Bcl-2, caspase-3 and the release of cytochrome c from mitochondria to cytoplasm.	Losartan	7-15	BCL2, apoptosis regulator	Rattus norvegicus	57-62	
28844872-6	2017	Our results showed that administration of losartan significantly inhibited the apoptosis by decreasing the number of apoptotic cells, decreasing the protein level of cleaved caspase-3, cytochrom C and Bax, and increasing the level of Bcl-2 both in vivo and in vitro.	Losartan	42-50	BCL2, apoptosis regulator	Rattus norvegicus	234-239	
23875703-8	2014	Losartan-induced up-regulation of HIF-1alpha and Wnt/beta-catenin signalling was associated with the recovery of IR-inhibited hepatic Bcl-2, Mn-SOD (manganese superoxide), Cu/Zn-SOD (copper/zinc superoxide) and GSH levels, and the suppression of IR-increased hepatic catalase and caspase 3/caspase 8 levels in MCD/HF-NASH rats.	Losartan	0-8	BCL2, apoptosis regulator	Rattus norvegicus	134-139	
19298698-13	2009	Losartan alone or in combination with simvastatin blocked the increased Bax expression and increased Bcl-2 expression.	Losartan	0-8	BCL2, apoptosis regulator	Rattus norvegicus	101-106	
17563572-10	2007	Losartan-treated Ang II-infused rats exhibited normalized systolic blood pressure, left ventricular weight, apoptosis, and Bax and Bcl-2 levels.	Losartan	0-8	BCL2, apoptosis regulator	Rattus norvegicus	131-136